AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
02 Dicembre 2021 - 3:00PM
Business Wire
AbCellera (Nasdaq: ABCL), a technology company with a
centralized operating system for next-generation antibody
discovery, announced today the appointment of Neil Aubuchon as
Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 years
of experience in strategic planning, operations, and leadership for
global biopharmaceutical companies, including tenures at Amgen and
Eli Lilly and Company (Lilly). As Chief Commercial Officer, Mr.
Aubuchon will lead the commercial strategy and assessment of
partnership opportunities to optimize the value of AbCellera’s
growing portfolio of royalty positions in the next generation of
antibody-based therapies.
“AbCellera is selective in partnering and evaluates potential
programs from the perspective of targets, teams, technical
feasibility, and market opportunity,” said Carl Hansen, Ph.D., CEO
and President of AbCellera. “Neil brings significant commercial
experience and a unique perspective for evaluating partnership
opportunities. We welcome him to our team, and believe his skills
will be invaluable as we continue to expand our business and evolve
our deal structures.”
“AbCellera has established a powerful technology for antibody
drug discovery that can quickly translate scientific discovery into
new therapies,” said Mr. Aubuchon. “Their technology leadership and
market position provide an exciting foundation from which to grow
the business. I am excited to join AbCellera, and I look forward to
leading efforts that will ultimately result in treatments for
patients in need.”
Prior to joining AbCellera, Mr. Aubuchon was the Global
Marketing Lead for Amgen's General Medicine early portfolio. In
this role, he was responsible for developing the integrated
strategy for Amgen's non-oncology therapeutic areas and leading
commercial strategy for more than 10 biologics, as well as several
high profile corporate initiatives. Prior to Amgen, Mr. Aubuchon
was the Vice President of Global Marketing at Santen, a global
ophthalmology-focused pharmaceutical company. Mr. Aubuchon
previously spent nearly 17 years at Lilly in various commercial
roles including, Chief Marketing Officer in Australia, Chief
Marketing Officer in Japan, Head of Strategy & Operations for
Lilly Bio-Medicines Globally, and Vice President of Lilly
Bio-Medicines in Japan.
About AbCellera Biologics Inc. AbCellera is a technology
company that searches, decodes, and analyzes natural immune systems
to find antibodies that its partners can develop into drugs to
prevent and treat disease. AbCellera partners with drug developers
of all sizes, from large pharmaceutical to small biotechnology
companies, empowering them to move quickly, reduce cost, and tackle
the toughest problems in drug development. For more information,
please visit www.abcellera.com.
AbCellera Forward-looking Statements This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
ability to develop, commercialize and achieve market acceptance of
our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211202005133/en/
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)
521-6774 Business Development: Neil Berkley; bd@abcellera.com,
+1(604) 559-9005 Investor Relations: Melanie Solomon;
ir@abcellera.com, +1(778) 729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024